Navigation Links
S*BIO Announces Collaboration with Onyx for JAK2 Inhibitors in the North American and European Markets
Date:1/6/2009

S*BIO Receives $25 Million Upfront Payment and Equity Investment and Eligible to Receive Additional $525 Million in Option & License Fees and Milestone Payments

SINGAPORE, Jan. 6 /PRNewswire/ -- S*BIO Pte Ltd today announced that the company has entered into a Development Collaboration, and Option & License Agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize S*BIO's novel JAK2 inhibitors, SB1518 and SB1578.

Under the terms of the agreement, S*BIO is eligible to receive up to $550 million in combined equity purchase, option & license fees, and development and sales milestone payments. This includes an upfront payment and upfront equity purchase totaling $25 million. S*Bio is also eligible to receive up to double digit royalties on any sales.

S*BIO will perform all the clinical development activities for SB1518 and preclinical to clinical development activities for SB1578 during the option period. Onyx can elect to exercise its exclusive options for SB1518 and SB1578 at certain predetermined stages of development for each product separately and independently. Each option converts into an exclusive license for development and commercialization rights for SB1518 and SB1578 in all indications in the United States, Canada and Europe where Onyx will assume all of the associated development costs. S*BIO has a co-funding option with respect to these development costs in return for enhanced royalties on any future product sales. S*BIO retains rights to develop and commercialize SB1518 and SB1578 in the rest of the world.

The development of SB1518 will initially focus on the treatment of myelofibrosis and other myeloproliferative diseases. JAK2 inhibitors are implicated across a broad range of difficult-to-treat illnesses, including cancer and autoimmune diseases.

"We are pleased to work with Onyx Pharmaceuticals and increase available reso
'/>"/>

SOURCE S*BIO
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrate Superior Profile of S*BIOs Novel Anti-Cancer Drug SB939
2. S*BIOs Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
3. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
4. MHA Announces Pegeen Butterfield, RN as Senior Vice President of Trade Relations
5. IMRIS announces first IMRISneuro project in Australia
6. Akrimax Pharmaceuticals Announces Manufacturing Partnership
7. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
8. American Asthma Foundation Announces Breakthrough Discovery
9. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
10. WellPoint Announces Innovative Program to Help Improve the Care of Members Suffering With Bipolar Disorder
11. DiFUSION Technologies Announces Company Launch Focused on Surgical Site Infections (SSIs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... September 01, 2014 An operating theatre ... hospital for performing surgical operations. An operating room comprises ... surgical booms, operating room lights, imaging displays as well ... report by Transparency Market Research, a U.S.-based market research ... reach USD 4.5 billion by 2019. , According ...
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. ... given to two American aid workers successfully cured a group ... researchers report. The drug, ZMapp, prompted recovery in all ... the medication until five days after infection. ZMapp even ... or even hours away from death, said study senior author ...
(Date:9/1/2014)... D.C. (PRWEB) September 01, 2014 The ... pleased to announce that Dawn Bazarko, DNP, MPH, RN, ... Fellows of the American Academy of Nursing. They will ... MBA, RN-BC, CCM, FACHE, whose induction we reported last ... October 18, 2014, during the 2014 American Academy of ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... August 31, 2014 Daily Gossip reveals ... resource and community that gives members access to thousands ... , This online resource aims to help both people ... as artists who are looking for inspiration in creating ... about Tattoo Me Now by visiting the official website ...
Breaking Medicine News(10 mins):Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... ARAY ), a global leader in the field of radiosurgery, ... Needham Life Sciences Conference in New York City, on Wednesday, June ... , A live webcast of the presentation will be available online ... http://www.accuray.com . The webcast replay ...
... to 25% drop in test scores, study found , THURSDAY, ... reason to be annoyed at other people,s cell phones, researchers ... ringtone can impair thinking, at least briefly. , Students unwittingly ... after a fellow "student,s" phone went off. , The finding ...
... to growing list of solutions available to help companies and ... , DEERFIELD, Ill., June 4 Knowledge and prevention are ... may look or feel healthy, you may not know about ... , , That is why Focused Health Solutions, a ...
... risk while ensuring accurate payments and compliance with Medicare standards , ... have ever wondered how to integrate Medicare Risk Adjustment with their ... latest release from Storan Technologies Inc. (STI). ... Merlin Medicare Risk Adjustment 6.0 (TM), a Web-based software solution ...
... June 4 Abbott (NYSE: ABT ) ... a New Drug Application (NDA) to the U.S. Food ... the treatment of mixed dyslipidemia, a combination of two ... "bad" cholesterol), high triglycerides and low HDL-cholesterol (the "good" ...
... , SUNNYVALE, Calif., June 4 - Cepheid (Nasdaq: ... for its symposium, "On-Demand HAI Testing: Good Medicine and ... 2009 Association for Professionals in Infection Control (APIC) annual ... - 10th. Cepheid,s GeneXpert(R) Systems and menu of molecular ...
Cached Medicine News:Health News:Accuray Incorporated to Present at Eighth Annual Needham Life Sciences Conference 2Health News:Stranger's Cell Phone Ring May Thwart Your Thinking 2Health News:Stranger's Cell Phone Ring May Thwart Your Thinking 3Health News:Focused Health Solutions Helps Make Preventative Health Screenings Simple and More Affordable 2Health News:Focused Health Solutions Helps Make Preventative Health Screenings Simple and More Affordable 3Health News:St. Louis Firm Brings Medicare Risk Adjustment to iPhone 2Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 2Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 3Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 4Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 5Health News:Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference 2Health News:Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference 3
(Date:9/1/2014)... NEW YORK , Sept. 1, 2014 /PRNewswire/ ... report is available in its catalogue:  Drug ... http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html ... diseases, such as cancer requires extensive expenditure, in ... first step in designing a new drug involves ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... The report firstly reviews the basic information of ... manufacturing technology. The report then explores global and ... their product specification, capacity, Production value, and market ...
(Date:8/29/2014)... Aug. 29, 2014 Pomerantz LLP has filed ... the "Company") (NASDAQ: EDAP ) and certain ... States District Court, Southern District of New ... behalf of a class consisting of all persons or ... and July 30, 2014, inclusive (the "Class Period"). This class ...
Breaking Medicine Technology:Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11Drug Discovery Technologies - A Global Market Overview 12Drug Discovery Technologies - A Global Market Overview 13Drug Discovery Technologies - A Global Market Overview 14X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3
... Epocal, Inc., a leading edge provider of point of ... and Drug Administration (FDA) clearance to market its new lactate ... the epoc System are used to evaluate acid-base status and ... of the blood).  The addition of lactate to the epoc ...
... , ANN ARBOR, Mich. , June 15 ... announced that its wholly-owned CLIA-certified clinical testing subsidiary, HartLab, ... a full array of microbiology testing.  Adeona believes that ... HartLab,s revenues in the current quarter and beyond and ...
Cached Medicine Technology:Epocal Announces FDA Clearance of Lactate Test 2Adeona Announces HartLab Expansion Into Microbiology Testing Services 2Adeona Announces HartLab Expansion Into Microbiology Testing Services 3Adeona Announces HartLab Expansion Into Microbiology Testing Services 4Adeona Announces HartLab Expansion Into Microbiology Testing Services 5
... Long-term biocompatibility is established. Provides a ... holes ensure correct positioning on the globe. ... ridge which, when covered by Tenons tissue, ... limiting postoperative hypotony. The range of implants ...
... Goldmann standard automatic or manual ... with white/white, blue/yellow or red/white stimuli/background ... or classic 4-2 threshold strategy. Examination ... grids (including 30-2, 24-2, and 10-2). ...
1-Meter Roll-Up Tangent Screen....
... 311 has additional hardware and software features ... most demanding clinics or teaching institutions. Standard ... test parameters for experimental or clinical studies. ... Capacity for further tests including Flicker- and ...
Medicine Products: